Core Insights - Autonomix Medical, Inc. is set to present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York, NY [1] - The company focuses on innovative technologies for diagnosing and treating diseases of the nervous system, with a first-in-class platform technology that includes a catheter-based microchip sensing array [4][5] - The initial application of this technology is aimed at treating pain associated with pancreatic cancer, a condition currently lacking reliable treatment options [5] Company Overview - Autonomix Medical, Inc. specializes in medical devices that aim to revolutionize the diagnosis and treatment of nervous system diseases [4] - The company's technology is designed to detect and differentiate neural signals with greater sensitivity than existing technologies, enabling transvascular diagnosis and treatment of peripheral nervous system diseases [4] - The investigational technology has not yet received marketing clearance in the United States [5] Conference Participation - Management will be available for in-person one-on-one meetings with qualified investors registered for the conference [2] - A video webcast of the presentation will be available on-demand starting September 8, 2025, at 7:00 AM ET, and will be archived for 90 days [3]

Core Insights - Autonomix Medical, Inc. has been granted a new patent, strengthening its position in a multi-billion-dollar market for medical devices targeting cardiovascular, renal, and other high-burden diseases [1][2] Patent and Technology - The newly issued Patent No. 3,697,298 ('298 patent) relates to a medical device that captures and processes physiological signals for real-time monitoring, applicable in various fields including coronary artery mapping and neurotherapy [1][3] - The '298 patent enhances the company's competitive edge by protecting its proprietary technology, which is expected to create diverse revenue streams and expand its global presence [2][3] Technology Platform - Autonomix's technology platform features a catheter-based microchip sensing array that can detect neural signals with greater sensitivity than existing technologies, enabling precision-guided treatment for conditions like chronic pain and hypertension [4][6] - The system includes distributed signal acquisition modules that improve data integrity during neural mapping, with key elements such as miniaturization and noise reduction [3][4] Development Focus - The company is initially focusing on developing its technology for treating pancreatic cancer, a condition associated with severe pain and lacking reliable treatment options [7] - The technology has the potential to address a wide range of indications, including cardiology and chronic pain management, across various disease categories [7]

Company Overview - Autonomix Medical, Inc. is a medical device company focused on advancing precision nerve-targeted treatments [2][3] - The company is developing a first-in-class platform system technology that includes a catheter-based microchip sensing array, which aims to detect and differentiate neural signals with greater sensitivity than current technologies [3][4] Technology and Applications - The initial focus of the technology is on treating pain, particularly in pancreatic cancer, which is known for causing debilitating pain and lacks reliable treatment options [4] - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management, across various diseases [4] Upcoming Events - The President and CEO of Autonomix, Brad Hauser, will participate in a virtual investor webinar hosted by Ladenburg Thalmann on August 21, 2025, at 1:00 PM ET [2][3] - The webinar will include a question and answer session, allowing participants to pre-submit questions [3]

Company Overview - Autonomix Medical, Inc. is a medical device company focused on advancing precision nerve-targeted treatments [3] - The company is developing a first-in-class platform system technology that includes a catheter-based microchip sensing array, which aims to detect and differentiate neural signals with greater sensitivity than current technologies [3] Technology and Applications - The initial focus of the technology is on treating pain, specifically targeting pancreatic cancer, which is known for causing debilitating pain and lacks reliable treatment options [4] - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management, across various diseases [4] - The technology is currently investigational and has not yet received marketing clearance in the United States [4] Upcoming Events - Autonomix will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, scheduled for August 19-21, 2025, with the presentation taking place on August 21, 2025, at 2:20 PM ET [1]

Core Insights - Autonomix Medical, Inc. has advanced its proprietary sensing catheter through a final design review, preparing for human clinical trials aimed at supporting a De Novo FDA application [1][3] - The innovative sensing catheter is the first intravascular device designed to detect and differentiate nerve signals in real time, enhancing treatment precision and reducing the risks of incomplete denervation or overtreatment [2][3] - The technology has the potential to transform neuromodulation and pain treatment, with applications across various therapeutic areas including cardiology, hypertension, and chronic pain management [3][6] Company Overview - Autonomix Medical, Inc. focuses on advancing innovative technologies for diagnosing and treating diseases involving the nervous system, utilizing a catheter-based microchip sensing array [5][6] - The company is initially developing its technology for treating pain associated with pancreatic cancer, a condition that currently lacks reliable treatment options [6] Development Milestones - The company is executing an operational plan to submit an Investigational Device Exemption (IDE) and commence U.S. clinical trials for the Autonomix Sensing and RF Ablation System, specifically targeting pancreatic cancer pain [4][6] - Completion of the design review milestone is seen as a significant step towards delivering safer and more effective treatment options for patients, while also creating value for shareholders [3]

Core Viewpoint - Autonomix Medical, Inc. (AMIX) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3][10] Earnings Estimates and Stock Performance - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, suggesting that upward revisions can lead to higher stock valuations [4][6] - For the fiscal year ending March 2026, Autonomix Medical is expected to earn -$2.73 per share, which remains unchanged from the previous year, but the Zacks Consensus Estimate has increased by 47.7% over the past three months [8] Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7] - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions and potential for market-beating returns [9][10]

Company Overview - Autonomix Medical, Inc. is a medical device company focused on advancing innovative technologies for diagnosing and treating diseases involving the nervous system [3] - The company's first-in-class platform system technology includes a catheter-based microchip sensing array that may detect and differentiate neural signals with greater sensitivity than current technologies [3] Technology Development - The initial focus of the technology is on the treatment of pain, particularly for pancreatic cancer, which causes debilitating pain and lacks reliable solutions [4] - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management [4] - The technology is currently investigational and has not yet received marketing clearance in the United States [4] Leadership and Engagement - Brad Hauser, the CEO of Autonomix, participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference, discussing his dedication to the company and its innovative technology [2] - The on-demand video webcast of the conference is available on the Virtual Investor website and the company's website [2]

Core Viewpoint - Autonomix Medical, Inc. has announced agreements for the immediate exercise of existing warrants, allowing the purchase of up to 1,477,596 shares of common stock at a reduced exercise price of $1.723 per share, expected to generate approximately $2.5 million in gross proceeds [1][4]. Group 1: Warrant Exercise and Financial Details - The company has entered into agreements with certain warrant holders for the immediate exercise of outstanding warrants, which were originally issued in November 2024 [1]. - The gross proceeds from the exercise of these warrants are anticipated to be around $2.5 million before placement agent fees [1]. - New unregistered warrants will be issued for the immediate exercise, allowing the purchase of the same number of shares at the same exercise price of $1.723 per share, valid for five and a half years [3]. Group 2: Transaction Closing and Use of Proceeds - The transaction is expected to close on or about July 23, 2025, pending customary closing conditions [4]. - The net proceeds from this offering will be utilized for working capital and general corporate purposes [4]. Group 3: Company Overview and Technology - Autonomix Medical is focused on advancing innovative technologies for diagnosing and treating diseases of the nervous system, utilizing a catheter-based microchip sensing array [7]. - The company is initially developing its technology for pain treatment, particularly targeting pancreatic cancer, and aims to address various conditions across a wide disease spectrum [8].

Core Viewpoint - Autonomix Medical, Inc. is enhancing its intellectual property portfolio with the issuance of U.S. Patent No. 12,295,646, which relates to a smart torquer device aimed at improving intravascular procedures, positioning the company for significant opportunities in a multi-billion-dollar market [1][2]. Group 1: Intellectual Property and Market Position - The company has over 80 issued patents and 40 pending applications, establishing a strong IP portfolio in nerve-sensing and modulation technologies [1]. - The newly issued '646 patent is designed to improve the manipulation of intravascular devices during minimally invasive procedures, integrating electronic components for better mechanical control and data communication [1][3]. - The smart torquer technology is expected to enhance control and signal integration in intravascular procedures, facilitating expansion into high-growth areas such as cardiology, neurosurgery, and interventional radiology [2]. Group 2: Technology and Applications - Autonomix's technology platform includes a catheter-based microchip sensing array that can detect and differentiate neural signals with greater sensitivity than existing technologies [4][6]. - The proprietary RF ablation technology allows for precision-guided interventions targeting specific nerves, which can address various diseases, including chronic pain and hypertension [4][7]. - Initial development efforts are focused on treating pain associated with pancreatic cancer, a condition currently lacking reliable treatment options [7].

Core Insights - Autonomix Medical, Inc. is advancing precision nerve-targeted treatments and has announced a follow-on market expansion study phase ("PoC 2") for its proof-of-concept trial [1] Company Overview - Autonomix is a medical device company focused on innovative technologies for diagnosing and treating diseases of the nervous system [3] - The company's first-in-class platform includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [3] - This technology aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases throughout the body [3] Technology Development - The initial focus of the technology is on treating pain, particularly in pancreatic cancer, which causes severe pain and lacks reliable treatment options [4] - The technology serves as a platform for addressing various indications, including cardiology, hypertension, and chronic pain management across a wide disease spectrum [4] - The technology is currently investigational and has not yet received marketing clearance in the United States [4]